Activated phosphoinositide 3-kinase delta syndrome (APDS), caused by mutations in PI3Kδ catalytic p110δ (PIK3CD) or regulatory p85α (PIK3R1) subunits, is a primary immunodeficiency affecting both humoral and cellular immunity, which shares some phenotypic similarities with hyper-IgM syndromes and common variable immunodeficiency (CVID). Since its first description in 2013, over 200 patients have been reported worldwide. Unsurprisingly, many of the newly diagnosed patients were recruited later in life from previously long-standing unclassified immunodeficiencies and the early course of the disease is, therefore, often less well-described. In this study, we report clinical and laboratory features of eight patients followed for APDS, with particular focus on early warning signs, longitudinal development of their symptoms, individual variations, and response to therapy. The main clinical features shared by our patients included recurrent bacterial and viral respiratory tract infections, gastrointestinal disease, non-malignant lymphoproliferation, autoimmune thyroiditis, and susceptibility to EBV. All patients tolerated vaccination with both attenuated live and subunit vaccines with no adverse effects, although some failed to mount adequate antibody response. Laboratory findings were characterized by dysgammaglobulinaemia, elevated serum IgM, block in B-cell maturation with high transitional B cells, and low naïve T cells with CD8 T-cell activation. All patients benefited from immunoglobulin replacement therapy, whereas immunosuppression with mTOR pathway inhibitors was only partially successful. Therapy with specific PI3K inhibitor leniolisib was beneficial in all patients in the clinical trial. These vignettes, summary data, and particular tell-tale signs should serve to facilitate early recognition, referral, and initiation of outcome-improving therapy.

Childhood Leukaemia Investigation Prague Department of Paediatric Haematology and Oncology 2nd Faculty of Medicine Charles University and University Hospital in Motol Prague Czechia

Department of Immunology 2nd Faculty of Medicine Charles University Hospital in Motol Prague Czechia

Department of Pediatrics 1st Faculty of Medicine Charles University Prague and Thomayer University Hospital Prague Czechia

Zobrazit více v PubMed

Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. (2003) 3:317–30. 10.1038/nri1056 PubMed DOI

Angulo I, Nejentsev S, Al E, Vadas O, Nejentsev S. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science. (2013) 342:866–72. 10.1126/science.1243292 PubMed DOI PMC

Deau M-C, Heurtier L, Frange P, Suarez F, Bole-feysot C, Nitschke P, et al. . A human immunodeficiency caused by mutations in the PIK3R1 gene. J Clin Invest. (2014) 124:3923–28. 10.1172/JCI75746 PubMed DOI PMC

Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, et al. . Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol. (2014) 15:88-97. 10.1038/ni.2771 PubMed DOI PMC

Lucas CL, Zhang Y, Venida A, Wang Y, Hughes J, McElwee J, et al. . Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. J Exp Med. (2014) 211:2537–47. 10.1084/jem.20141759 PubMed DOI PMC

Chiriaco M, Brigida I, Ariganello P, Di Cesare S, Di Matteo G, Taus F, et al. . The case of an APDS patient: defects in maturation and function and decreased in vitro anti-mycobacterial activity in the myeloid compartment. Clin Immunol. (2015) 178:20–8. 10.1016/j.clim.2015.12.008 PubMed DOI

Wentink MWJ, Mueller YM, Dalm VASH, Driessen GJ, van Hagen PM, van Montfrans JM, et al. . Exhaustion of the CD8 + T cell compartment in patients with mutations in phosphoinositide 3-kinase delta. Front Immunol. (2018) 9:1–15. 10.3389/fimmu.2018.00446 PubMed DOI PMC

Elkaim E, Neven B, Bruneau J, Mitsui-Sekinaka K, Stanislas A, Heurtier L, et al. . Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase delta syndrome 2: a cohort study. J Allergy Clin Immunol. (2015) 138:210–8. 10.1016/j.jaci.2016.03.022 PubMed DOI

Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, et al. . Clinical spectrum and features of activated PI3-kinase delta syndrome: a large patient cohort study. J Allergy Clin Immunol. (2016) 139:597–606.e4. 10.1016/j.jaci.2016.06.021 PubMed DOI PMC

Parackova Z, Bloomfield M, Vrabcova P, Zentsova I, Klocperk A, Milota T, et al. . Mutual alteration of NOD2-associated Blau syndrome and IFNγR1 deficiency. J Clin Immunol. (2019) 40:165–178. 10.1007/s10875-019-00720-6 PubMed DOI

Schatorjé EJH, Gemen EFA, Driessen GJA, Leuvenink J, van Hout RWNM, de Vries E. Paediatric reference values for the peripheral T cell compartment. Scand J Immunol. (2012) 75:436–44. 10.1111/j.1365-3083.2012.02671.x PubMed DOI

Piatosa B, Wolska-Kuśnierz B, Pac M, Siewiera K, Gałkowska E, Bernatowska E, et al. . B cell subsets in healthy children: reference values for evaluation of B cell maturation process in peripheral blood. Cytometry B Clin Cytom. (2010) 78:372–81. 10.1002/cyto.b.20536 PubMed DOI

Cunningham-Rundles C. The many faces of common variable immunodeficiency. Hematol Am Soc Hematol Educ Progr. (2012) 301–5. 10.1182/asheducation.V2012.1.301.3798316 PubMed DOI PMC

Gámez-Díaz L, August D, Stepensky P, Revel-Vilk S, Seidel MG, Noriko M, et al. . The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency. J Allergy Clin Immunol. (2016) 137:223–30. 10.1016/j.jaci.2015.09.025 PubMed DOI

Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, et al. . Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. (2015) 349:436–40. 10.1126/science.aaa1663 PubMed DOI

Parackova Z, Milota T, Vrabcova P, Smetanova J, Svaton M, Freiberger T, et al. . Novel XIAP mutation causing enhanced spontaneous apoptosis and disturbed NOD2 signalling in a patient with atypical adult-onset Crohn's disease. Cell Death Dis. (2020) 11:430. 10.1038/s41419-020-2652-4 PubMed DOI PMC

Kuijk LM, Beekman JM, Koster J, Waterham HR, Frenkel J, Coffer PJ. HMG-CoA reductase inhibition induces IL-12 release through Rac1/PI3K/PKB-dependent caspase-1 activation. Blood. (2008) 112:3563–73. 10.1182/blood-2008-03-144667 PubMed DOI

Eickholt BJ, Ahmed AI, Davies M, Papakonstanti EA, Pearce W, Starkey ML, et al. . Control of axonal growth and regeneration of sensory neurons by the p110δ PI 3-kinase. PLoS ONE. (2007) 2:1–9. 10.1371/journal.pone.0000869 PubMed DOI PMC

Okano T, Imai K, Tsujita Y, Mitsuiki N, Yoshida K, Kamae C, et al. . Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase δ syndrome type 1. J Allergy Clin Immunol. (2019) 143:266–75. 10.1016/j.jaci.2018.04.032 PubMed DOI

Rao VK, Webster S, Dalm VASH, Šedivá A, Van Hagen PM, et al. . Effective “activated PI3Kδ syndrome”–targeted therapy with the PI3Kδ inhibitor leniolisib. Blood. (2017) 130:2307–316. 10.1182/blood-2017-08-801191 PubMed DOI PMC

Mensa-Vilaró A, Bravo García-Morato M, de la Calle-Martin O, Franco-Jarava C, Martínez-Saavedra MT, González-Granado LI, et al. . Unexpected relevant role of gene mosaicism in patients with primary immunodeficiency diseases. J Allergy Clin Immunol. (2019) 143:359–68. 10.1016/j.jaci.2018.09.009 PubMed DOI

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome